Adjuvant pembrolizumab affects fatigue but not HRQOL in muscle-invasive UC.
| Publicado en: | Urology Times Vol. 54; no. 5; pp. 22 - 24 |
|---|---|
| Autor principal: | |
| Formato: | pictorial Journal Article |
| Publicado: |
MJH Life Sciences
Jul/Aug2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=195314685&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 195314685 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00939722 URO jtl: Urology Times issn: 00939722 maglogo: N pubinfo: dt: Jul/Aug2026 vid: 54 iid: 5 pid: 54670 pub: MJH Life Sciences place: Cranbury, New Jersey artinfo: ui: 195314685 195314685 195314685 195314685 ppf: 22 ppct: 2 formats: fmt: @attributes: type: P tig: atl: Adjuvant pembrolizumab affects fatigue but not HRQOL in muscle-invasive UC. aug: au: SAYLOR, BENJAMIN P. sug: subj: Neoplasm Invasiveness Surgery Carcinoma, Transitional Cell Surgery Carcinoma, Transitional Cell Drug Therapy Chemotherapy, Adjuvant Neoplasm Invasiveness Drug Therapy Antibodies, Monoclonal Therapeutic Use Programmed Cell Death Ligand 1 Antagonists and Inhibitors Cancer Fatigue Prevention and Control Dyspnea Prevention and Control Quality of Life Evaluation Drug Efficacy Nausea and Vomiting Prevention and Control Activities of Daily Living Walking Physical Activity Functional Status Sexuality Urination Disorders Prevention and Control Overall Survival Patient-Reported Outcomes Antibodies, Monoclonal Adverse Effects pubtype: Academic Journal doctype: pictorial Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|